{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T03:33:06Z","timestamp":1778643186288,"version":"3.51.4"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.bioorg.2020.104176","type":"journal-article","created":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T11:32:45Z","timestamp":1598441565000},"page":"104176","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Design and synthesis of novel desfluoroquinolone-aminopyrimidine hybrids as potent anti-MRSA agents with low hERG activity"],"prefix":"10.1016","volume":"103","author":[{"given":"Runzhe","family":"Song","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minghui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruixuan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Song","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cai-Guang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongsheng","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siyuan","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianfeng","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renhua","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiuqin","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2020.104176_b0005","unstructured":"Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States; 2019. https:\/\/www.cdc.gov\/drugresistance\/pdf\/threats-report\/2019-ar-threats-report-508.pdf."},{"key":"10.1016\/j.bioorg.2020.104176_b0010","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1056\/NEJMe058023","article-title":"Community-associated MRSA-resistance and virulence converge","volume":"352","author":"Chambers","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioorg.2020.104176_b0015","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1056\/NEJMoa055356","article-title":"aureus infections among patients in the emergency department","volume":"355","author":"Moran","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioorg.2020.104176_h0020","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.annemergmed.2004.10.011","article-title":"High Prevalence of methicillin-resistant staphylococcus aureus in emergency department skin and soft tissue infections","volume":"45","author":"Frazee","year":"2005","journal-title":"Ann. Emerg. Med."},{"key":"10.1016\/j.bioorg.2020.104176_h0025","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa043252","article-title":"Methicillin-resistant staphylococcus aureus disease in three communities","volume":"352","author":"Fridkin","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioorg.2020.104176_h0030","doi-asserted-by":"crossref","first-page":"928","DOI":"10.3201\/eid1106.040641","article-title":"Methicillin-resistant staphylococcus aureus in community-acquired skin infections","volume":"11","author":"Moran","year":"2005","journal-title":"Emerging Infect. Dis."},{"key":"10.1016\/j.bioorg.2020.104176_b0025","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S1473-3099(01)00091-3","article-title":"Vancomycin-resistant staphylococcus aureus: a new model of antibiotic resistance","volume":"1","author":"Hiramatsu","year":"2001","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.bioorg.2020.104176_b0030","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1093\/jac\/dkg104","article-title":"Linezolid resistance in clinical isolates of staphylococcus aureus","volume":"51","author":"Wilson","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.bioorg.2020.104176_b0035","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1093\/jac\/40.1.135","article-title":"Methicillin resistant S. aureus clinical strain with reduced vancomycin susceptibility","volume":"40","author":"Hiramatsu","year":"1997","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.bioorg.2020.104176_h0050","first-page":"429","article-title":"Vancomycin intermediate and resistant S aureus: What infectious disease specialists need to know","volume":"32","author":"Fridkin","year":"2001","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.bioorg.2020.104176_h0055","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/cjoc.201800470","article-title":"Chemical Intervention on Staphylococcus aureus Virulence","volume":"37","author":"Zhou","year":"2019","journal-title":"Chin. J. Chem."},{"key":"10.1016\/j.bioorg.2020.104176_h9000","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.ejmech.2018.08.050","article-title":"Synthesis and antibacterial evaluation of 13-substituted cycloberberine derivatives as a novel class of anti-MRSA agents","volume":"157","author":"Fan","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2020.104176_h9005","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1021\/acs.jmedchem.7b01300","article-title":"Novel terminal bipheny-based diapophytoene desaturases (CrtN) inhibitors as anti-MRSA\/VISR\/LRSA agents with reduced hERG activity","volume":"61","author":"Li","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2020.104176_h9010","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.bioorg.2018.08.012","article-title":"Synthesis of new 3-phenylquinazolin-4(3H)-one derivatives as potent antibacterial agents effective against methicillin- and vancomycin-resistant Staphylococcus aureus (MRSA and VRSA)","volume":"81","author":"Gatadi","year":"2018","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2020.104176_h9015","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1021\/acsinfecdis.9b00222","article-title":"Toward broad spectrum dihydrofolate reductase inhibitors targeting trimethoprim resistant enzymes identified in clinical isolates of methicillin resistant Staphylococcus aureus","volume":"5","author":"Reeve","year":"2019","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.bioorg.2020.104176_h9020","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.bioorg.2018.11.007","article-title":"Synthesis and evaluation of new 4-oxoquinazolin-3(4H)-yl)benzoic acid and benzamide derivatives as potent antibacterial agents effective against multidrug resistant Staphylococcus aureus","volume":"83","author":"Gatadi","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2020.104176_h9025","doi-asserted-by":"crossref","first-page":"5287","DOI":"10.1021\/acs.jmedchem.0c00153","article-title":"Exploration of the Structural Space in 4(3H)-Quinazolinone Antibacterials","volume":"63","author":"Qian","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2020.104176_h9030","article-title":"Promising antibacterial agents against multidrug resistant Staphylococcus aureus","volume":"92","author":"Gatadia","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2020.104176_b0050","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.ejmech.2017.11.082","article-title":"4-Quinolone derivatives and their activities against Gram positive pathogens","volume":"143","author":"Zhang","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2020.104176_b0055","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1517\/13543784.8.2.181","article-title":"Moxifloxacin (Bay 12\u20138039): a new methoxy quinolone antibacterial","volume":"8","author":"MacGowan","year":"1999","journal-title":"Exp. Opin. Invest. Drugs"},{"key":"10.1016\/j.bioorg.2020.104176_b0060","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1093\/cid\/ciy600","article-title":"Delafloxacin: A New Anti\u2013methicillin-resistant Staphylococcus aureus fluoroquinolone","volume":"68","author":"Saravolaz","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.bioorg.2020.104176_b0065","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1093\/jac\/46.4.633","article-title":"Sitafloxacin in the treatment of patients with infections caused by vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus","volume":"46","author":"Shetty","year":"2000","journal-title":"J. Antimicro. Chemother."},{"key":"10.1016\/j.bioorg.2020.104176_h0080","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0014-2999(00)00693-2","article-title":"Effects of fluoroquinolones on hERG currents","volume":"406","author":"Bischoff","year":"2000","journal-title":"Eur. J. Pharmcol."},{"key":"10.1016\/j.bioorg.2020.104176_h0085","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1093\/jac\/49.4.593","article-title":"Cardiotoxicity of fluoroquinolones","volume":"49","author":"Rubinstein","year":"2002","journal-title":"J. Antimicrob. Chemoth."},{"key":"10.1016\/j.bioorg.2020.104176_b0075","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1111\/j.1540-8159.2003.00367.x","article-title":"Quinolones: cardioprotective or cardiotoxic?","volume":"26","author":"Katritsis","year":"2003","journal-title":"Pacing Clin. electrophysiol."},{"key":"10.1016\/j.bioorg.2020.104176_b0080","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/jac\/49.3.455","article-title":"In vitro and in vivo antibacterial activity of T-3912, a novel non-fluorinated topical quinolone","volume":"49","author":"Yamakawa","year":"2002","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.bioorg.2020.104176_b0085","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1128\/AAC.47.1.161-165.2003","article-title":"In vitro susceptibilities to and bactericidal activities of garenoxacin (BMS-284756) and other antimicrobial agents against human mycoplasmas and ureaplasmas","volume":"47","author":"Waites","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bioorg.2020.104176_b0090","doi-asserted-by":"crossref","first-page":"4915","DOI":"10.1128\/AAC.00078-09","article-title":"G. In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates","volume":"53","author":"Adam","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bioorg.2020.104176_h0110","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.2174\/092986707781058805","article-title":"Molecular hybridization: a useful tool in the design of new drug prototypes","volume":"14","author":"Viegas-Junior","year":"2007","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.bioorg.2020.104176_h0115","doi-asserted-by":"crossref","first-page":"6973","DOI":"10.1021\/jm049637+","article-title":"Drug evolution concept in drug design: 1. hybridization method","volume":"47","author":"Lazar","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2020.104176_b0100","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1016\/j.ejmech.2008.10.018","article-title":"A novel and efficient one step synthesis of 2-amino-5-cyano-6-hydroxy-4-aryl pyrimidines and their anti-bacterial activity","volume":"44","author":"Deshmukh","year":"2009","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2020.104176_b0105","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1128\/AAC.40.10.2321","article-title":"Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae","volume":"40","author":"Pan","year":"1996","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bioorg.2020.104176_h0130","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1128\/AAC.01617-06","article-title":"Quinolone-mediated bacterial death","volume":"52","author":"Drlica","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bioorg.2020.104176_h0135","doi-asserted-by":"crossref","first-page":"981","DOI":"10.2174\/156802609789630947","article-title":"Quinolones: action and resistance updated","volume":"9","author":"Drlica","year":"2009","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.bioorg.2020.104176_b0115","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1021\/bi5000564","article-title":"Mechanism of quinolone action and resistance","volume":"53","author":"Aldred","year":"2014","journal-title":"Biochemistry"},{"key":"10.1016\/j.bioorg.2020.104176_b0120","doi-asserted-by":"crossref","first-page":"160157","DOI":"10.1098\/rsob.160157","article-title":"Exploring the active site of the Streptococcus pneumoniae topoisomerase IV \u2013DNA cleavage complex with novel 7,8-bridged fluoroquinolones","volume":"6","author":"Laponogov","year":"2016","journal-title":"Open Biol."},{"key":"10.1016\/j.bioorg.2020.104176_b0125","doi-asserted-by":"crossref","first-page":"3860","DOI":"10.1016\/j.bmc.2015.03.037","article-title":"Anti-HIV diarylpyrimidine-quinolone hybrids and their mode of action","volume":"23","author":"Mao","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2020.104176_b0130","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.ejmech.2017.01.012","article-title":"The synthesis and antistaphylococcal activity of 9, 13-disubstituted berberine derivatives","volume":"127","author":"Wang","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2020.104176_b0135","doi-asserted-by":"crossref","first-page":"4263","DOI":"10.1016\/j.bmc.2016.07.020","article-title":"Synthesis and anticancer potential of novel xanthone derivatives with 3, 6-substituted chains","volume":"24","author":"Liu","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2020.104176_b0140","doi-asserted-by":"crossref","first-page":"4558","DOI":"10.1021\/jm500270w","article-title":"Membrane active vancomycin analogues: a strategy to combat bacterial resistance","volume":"57","author":"Yarlagadda","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2020.104176_b0145","doi-asserted-by":"crossref","first-page":"9786","DOI":"10.1073\/pnas.0402521101","article-title":"Complete genomes of two clinical Staphylococcus aureus strains: Evidence for the rapid evolution of virulence and drug resistance","volume":"101","author":"Holden","year":"2004","journal-title":"Proc. Natl. Acad. Sci."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206820314735?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206820314735?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T08:11:10Z","timestamp":1758615070000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206820314735"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":41,"alternative-id":["S0045206820314735"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2020.104176","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design and synthesis of novel desfluoroquinolone-aminopyrimidine hybrids as potent anti-MRSA agents with low hERG activity","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2020.104176","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104176"}}